Practice parameters for anal squamous neoplasms

Diseases of the Colon and Rectum

Volumn 55, Issue 7, 2012, Pages 735-749

  Steele, Scott R ^a   Varma, Madhulika G ^a   Melton, Genevieve B ^a   Ross, Howard M ^a   Rafferty, Janice F ^a   Buie, W Donald ^a  

^a NONE

Author keywords

Anal cancer; Anal condyloma; Anal epidermoid carcinoma; Anal intraepithelial neoplasia; Anal neoplasms

Indexed keywords

AMINOLEVULINIC ACID; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CISPLATIN; FLUOROURACIL; IMIQUIMOD; MITOMYCIN C; WART VIRUS VACCINE;

ANAL CANAL; ANOPLASTY; ANTIVIRAL THERAPY; ANUS CARCINOMA; ANUS SQUAMOUS NEOPLASM; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CD4 LYMPHOCYTE COUNT; CHEMORADIOTHERAPY; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONDYLOMA ACUMINATUM; DIAGNOSTIC ACCURACY; DIGITAL RECTAL EXAMINATION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TOLERABILITY; ECHOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HIGH GRADE ANUS INTRAEPITHELIAL NEOPLASIA; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMAGE QUALITY; INDUCTION CHEMOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; LOW GRADE ANUS INTRAEPITHELIAL NEOPLASIA; MALE HOMOSEXUAL; MEDICAL HISTORY; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATION; OVERALL SURVIVAL; PAPANICOLAOU TEST; PATIENT ASSESSMENT; PATIENT MONITORING; PHOTODYNAMIC THERAPY; PHYSICAL EXAMINATION; RADIATION DOSE FRACTIONATION; RECTUM ABDOMINOPERINEAL RESECTION; RECTUM BIOPSY; SALVAGE THERAPY; SENTINEL LYMPH NODE BIOPSY; SENTINEL LYMPH NODE METASTASIS; SIGMOIDOSCOPY; SQUAMOUS CELL CARCINOMA; SYSTEMIC THERAPY; TARGET CELL DESTRUCTION; VACCINATION;

ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; EVIDENCE-BASED MEDICINE; HUMANS; LYMPHATIC METASTASIS; NEOPLASM STAGING;

EID: 84863643577     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1097/DCR.0b013e318255815e     Document Type: Article

References (195)

1. American Cancer Society. Cancer Facts & Figures 2010. Atlanta, GA: American Cancer Society; 2010. Available at http://www.cancer.org/acs/groups/ content/@epidemiologysurveilance/documents/document/acspc-026238.pdf Accessed November 11, 2011.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66. (Pubitemid 46148091)
3. Uronis HE, Bendell JC. Anal cancer: an overview. Oncologist. 2007;12:524-534. (Pubitemid 350012115)
4. Gordon PH. Current status: perianal and anal canal neoplasms. Dis Colon Rectum. 1990;33:799-808. (Pubitemid 20308171)
5. Johnson LG, Madeleine MM, Newcomer LM, Schwartz SM, Daling JR. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer. 2004;101:281-288. (Pubitemid 38890830)
6. Abbas A, Yang G, Fakih M. Management of anal cancer in 2010. Part 1: Overview, screening, and diagnosis. Oncology (Williston Park). 2010;24:364-369.
7. Frisch M, Glimelius B, van den Brule AJC, et al. Sexually transmitted infection as a cause of anal cancer. N Engl J Med. 1997;337:1350-1358. (Pubitemid 27467769)
8. Welton ML, Varma MG. Anal cancer. In: Wolff BG, Fleshman JW, Beck DE, et al, eds. The ASCRS Textbook of Colon and Rectal Surgery. New York, NY: Springer Science+Business Media, LLC; 2007:482-500.
9. Bean SM, Chhieng DC. Anal-rectal cytology: a review. Diagn Cytopathol. 2010;38:538-546.
10. Bullard Dunn KM, Rothenberger DA. Colon, rectum, and anus. Chapter 29. In: Brunicardi FC, Andersen DK, Billiar TR, Dunn DL, Hunter JG, Matthews JB, Pollock RE, eds. Schwartz's Principles of Surgery. 9th ed. http://www. accessmedicine.com. Accessed May 10, 2012.
11. Martin F, Bower M. Anal intraepithelial neoplasia in HIV positive people. Sex Transm Infect. 2001;77:327-331. (Pubitemid 32964266)
12. Nahas CS, Lin O, Weiser MR, Temple LK, Wong WD, Stier EA. Prevalence of perianal intraepithelial neoplasia in HIV-infected patients referred for high-resolution anoscopy. Dis Colon Rectum. 2006;49:1581-1586. (Pubitemid 44796130)
13. Santoso JT, Long M, Crigger M, Wan JY, Haefner HK. Anal intraepithelial neoplasia in women with genital intraepithelial neoplasia. Obstet Gynecol. 2010;116:578-582.
14. Park IU, Ogilvie JW Jr, Anderson KE, Li ZZ, Darrah L, Madoff R, Downs L Jr. Anal human papillomavirus infection and abnormal anal cytology in women with genital neoplasia. Gynecol Oncol. 2009;114:399-403.
15. Patel HS, Silver AR, Levine T, Williams G, Northover JM. Human papillomavirus infection and anal dysplasia in renal transplant recipients. Br J Surg. 2010;97:1716-1721.
16. Ogilvie JW Jr, Park IU, Downs LS, Anderson KE, Hansberger J, Madoff RD. Anal dysplasia in kidney transplant recipients. J Am Coll Surg. 2008;207:914-921.
17. Anus. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual. 7th ed., New York, NY: Springer; 2010:165-173.
18. Fleshner PR, Chalasani S, Chang GJ, Levien DH, Hyman NH, Buie WD, and the Standards Practice Task Force of The American Society of Colon and Rectal Surgeons. Practice Parameters for anal squamous neoplasms. Dis Colon Rectum. 2008;51:2-9.
19. Guyatt G, Gutterman D, Baumann MH, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians Task Force. Chest. 2006;129:174-181. (Pubitemid 43265259)
20. Klas JV, Rothenberger DA, Wong WD, et al. Malignant tumors of the anal canal: the spectrum of disease, treatment, and outcomes. Cancer. 1999;85:1686-1693. (Pubitemid 29169668)
21. Ryan DP, Compton CC, Mayer RJ. Carcinoma of the anal canal. N Engl J Med. 2000;342:792-800. (Pubitemid 30151924)
22. Robb BW, Mutch MG. Epidermoid carcinoma of the anal canal. Clin Colon Rectal Surg. 2006;19:54-60. (Pubitemid 43855636)
23. Tanum G, Tveit K, Karlsen KO. Diagnosis of anal carcinoma: doctor's finger still the best? Oncology. 1991;48:383-386.
24. Welton ML, Sharkey FE, Kahlenberg MS. The etiology and epidemiology of anal cancer. Surg Oncol Clin N Am. 2004;13:263-275. (Pubitemid 38609353)
25. Frisch M, Glimelius B, van den Brule AJ, et al. Sexually transmitted infection as a cause of anal cancer. N Engl J Med. 1997;337:1350-1358. (Pubitemid 27467769)
26. Daling JR, Weiss NS, Hislop TG et al. Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med. 1987;317:973-977. (Pubitemid 17147952)
27. Daling JR, Sherman KJ, Hislop TG, et al. Cigarette smoking and the risk of anogenital cancer. Am J Epidemiol. 1992;135:180-189.
28. Chiao EY, Krown SE, Stier EA, et al. A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic. J Acquir Immune Defic Syndr. 2005;40:451-455. (Pubitemid 41669180)
29. Palefsky JM, Holly EA, Ralston ML, et al. High incidence of anal high grade squamous intra-epithelial lesions among HIV-positive and HIV negative homosexual and bisexual men. AIDS. 1998;12:495-503. (Pubitemid 28116159)
30. Anal canal. In: Greene FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002:125-130.
31. Grabenbauer GG, Kessler H, Matzel KE, Sauer R, Hohenberger W, Schneider IH. Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients. Dis Colon Rectum. 2005;48:1742-1751. (Pubitemid 41243129)
32. Wasvary HJ, Barkel DC, Klein SN. Is total colonic evaluation for anal cancer necessary? Am Surg. 2000;66:592-594. (Pubitemid 30396253)
33. Klompje J, Petrelli NJ, Herrera L, Mittelman A. Synchronous and metachronous colon lesions in squamous cell carcinoma of the anal canal. J Surg Oncol. 1987;35:86-88. (Pubitemid 17092940)
34. Giovannini M, Bardou VJ, Barclay R, et al. Anal carcinoma: prognostic value of endorectal ultrasound (ERUS). Results of a prospective multicenter study. Endoscopy. 2001;33:231-236. (Pubitemid 32586397)
35. Jacopo M. Endoanal ultrasound for anal cancer staging. Int J Colorectal Dis. 2011;26:385-386.
36. Otto SD, Lee L, Buhr HJ, Frericks B, Höcht S, Kroesen AJ. Staging anal cancer: prospective comparison of transanal endoscopic ultrasound and magnetic resonance imaging. Gastrointest Surg. 2009;13:1292-1298.
37. Trautmann TG, Zuger JH. Positron emission tomography for pretreatment staging and posttreatment evaluation in cancer of the anal canal. Mol Imaging Biol. 2005;7:309-313.
38. Cotter SE, Grigsby PW, Siegel BA, et al.. FDG-PET/CT in the evaluation of anal carcinoma. Int J Radiat Oncol Biol Phys. 2006;65:720-725. (Pubitemid 43795859)
39. Krengli M, Milia ME, Turri L, et al. FDG-PET/CT imaging for staging and target volume delineation in conformal radiotherapy of anal carcinoma. Radiat Oncol. 2010;5:10.
40. Nguyen BT, Joon DL, Khoo V, et al. Assessing the impact of FDG-PET in the management of anal cancer. Radiother Oncol. 2008;87:376-382.
41. Kidd EA, Dehdashti F, Siegel BA, Grigsby PW. Anal cancer maximum F-18 fluorodeoxyglucose uptake on positron emission tomography is correlated with prognosis. Radiother Oncol. 2010;95:288-291.
42. Mistrangelo M, Pelosi E, Bellò M, et al. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of inguinal node metastases in patients with anal cancer. Int J Radiat Oncol Biol Phys. 2010;77:73-78.
43. De Nardi P, Carvello M, Canevari C, Passoni P, Staudacher C. Sentinel node biopsy in squamous-cell carcinoma of the anal canal. Ann Surg Oncol. 2011;18:365-370.
44. Hirche C, Dresel S, Krempien R, Hünerbein M. Sentinel node biopsy by indocyanine green retention fluorescence detection for inguinal lymph node staging of anal cancer: preliminary experience. Ann Surg Oncol. 2010;17:2357-2362.
45. de Jong JS, Beukema JC, van Dam GM, Slart R, Lemstra C, Wiggers T. Limited value of staging squamous cell carcinoma of the anal margin and canal using the sentinel lymph node procedure: a prospective study with long-term follow-up. Ann Surg Oncol. 2010;17:2656-2662.
46. Buroker TR, Nigro N, Bradley G, et al. Combined therapy for cancer of the anal canal: a follow-up report. Dis Colon Rectum. 1977;20:677-678. (Pubitemid 8248303)
47. Nigro ND, Vaitkevicius VK, Buroker T, et al. Combined therapy for cancer of the anal canal. Dis Colon Rectum. 1981;24:73-75. (Pubitemid 11113350)
48. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, Halverson AL. Squamous cell carcinoma of the anal canal: utilization and outcomes of recommended treatment in the United States. Ann Surg Oncol. 2008;15:1948-1958.
49. Young SC, Solomon MJ, Hruby G, Frizelle FA. Review of 120 anal cancer patients. Colorectal Dis. 2009;11:909-914.
50. Glynne-Jones R, Meadows H, Wan S, et al. National Cancer Research Institute Anal Sub Group and Colorectal Clinical Oncology Group. EXTRA-a multicenter phase IIstudy of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. Int J Radiat Oncol Biol Phys. 2008;72:119-126.
51. Cummings BJ, Keane TJ, O'Sullivan B, Wong CS, Catton CN. Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. Int J Rad Oncol Biol Phys. 1991;21:1115-1125.
52. Raffetto N, Monaco A, Banelli E. Radiotherapy and chemotherapy in the conservative treatment of anal canal carcinoma. Anticancer Res. 2008;28(2B):1335-1339. (Pubitemid 351578875)
53. Arnott SJ, Cunningham JD, Gallagher J, et al. UKCCCR Anal Cancer Trial Working Party. Epidermoid anal cancer: results from the UKCCCR randomized trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet. 1996;348:1049-1054. (Pubitemid 26343598)
54. Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase 3 randomized intergroup study. J Clin Oncol. 1996;14:2527-2539. (Pubitemid 26300120)
55. Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of Phase 3 randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997;15:2040-2049. (Pubitemid 27209535)
56. Rabbani AN, Zlotecki RA, Kirwan J, George TJ Jr, Morris CG, Rout WR, Mendenhall WM. Definitive radiotherapy for squamous cell carcinoma of the anal canal. Am J Clin Oncol. 2010;33:47-51.
57. Balamucki CJ, Zlotecki RA, Rout WR, et al. Squamous cell carcinoma of the anal margin: the University of Florida experience. Am J Clin Oncol. 2011;34:406-410.
58. Fuchshuber PR, Rodriguez-Bigas M, Weber T, Petrelli NJ. Anal canal and perianal epidermoid cancers. J Am Coll Surg. 1997;185:494-505. (Pubitemid 27475451)
59. Hatfield P, Cooper R, Sebag-Montefiore D. Involved-field, low-dose chemoradiotherapy for early-stage anal carcinoma. Int J Radiat Oncol Biol Phys. 2008;70:419-424.
60. Chen YW, Yen SH, Chen SY, et al. Anus-preservation treatment for anal cancer: retrospective analysis at a single institution. J Surg Oncol. 2007;96:374-380.
61. Hodges JC, Das P, Eng C, et al. Intensity-modulated radiation therapy for the treatment of squamous cell anal cancer with para-aortic nodal involvement. Int J Radiat Oncol Biol Phys. 2009;75:791-794.
62. Salama JK, Mell LK, Schomas DA, et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol. 2007;25:4581-4586. (Pubitemid 350035316)
63. Pepek JM, Willett CG, Wu QJ, et al. Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis. Int J Radiat Oncol Biol Phys. 2010;78:1413-1419.
64. Lisbona A, Averbeck D, Supiot S, et al. IM1T combined to IGRT: increase of the irradiated volume. Consequences? [in French]. Cancer Radiother. 2010;14:563-570.
65. Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys. 2006;65:1-7.
66. Jiang Y, Mackley H, Cheng H, Ajani JA. Anal carcinoma therapy: can we improve on 5 fluorouracil/mitomycin/radiotherapy? J Natl Compr Canc Netw. 2010;8:135-144.
67. Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;299:1914-1921. (Pubitemid 351574921)
68. Ajani JA, Winter KA, Gunderson LL, et al. US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. J Clin Oncol. 2009;27:1116-1121.
69. James R, Wan S, Glynne-Jones R, et al. A randomized trial of chemoradiation using mitomycin or cisplatin with of without maintenance cisplatin/5FUin squamous cell carcinoma of the anus (ACT II). J Clin Oncol. 2009;27;1149.
70. Olivatto LO, Cabral V, Rosa A, et al. Mitomycin-C- or cisplatin-based chemoradiotherapy for anal canal carcinoma: long-term results. Int J Radiat Oncol Biol Phys. 2011;79:490-495.
71. Meropol NJ, Niedzwiecki D, Shank B, et al. Induction therapy for poor-prognosis anal canal carcinoma: a phase IIstudy of the cancer and Leukemia Group B (CALGB 9281). J Clin Oncol. 2008; 26: 3229-3234.
72. Matzinger O, Roelofsen F, Mineur L, et al; EORTC Radiation Oncology and Gastrointestinal Tract Cancer Groups. Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase IIstudy 22011-40014). Eur J Cancer. 2009;45:2782-2791.
73. Crehange G, Bosset M, Lorchel F, et al. Combining cisplatin and mitomycin with radiotherapy in anal carcinoma. Dis Colon Rectum. 2007;50:43-49.
74. Ben-Josef E, Moughan J, Ajani JA, et al. Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group Trials 87-04 and 98-11. J Clin Oncol. 2010 28:5061-5066.
75. Hannoun-Levi JM, Ortholan C, Resbeut M, et al. High-dose split-course radiation therapy for anal cancer: outcome analysis regarding the boost strategy (CORS-03 Study). Int J Radiat Oncol Biol Phys. 2011;80:712-720.
76. Widder J, Kastenberger R, Fercher E, et al. Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients. Radiother Oncol. 2008;87:367-375.
77. Glynne-Jones R, Sebag-Montefiore D, Adams R, et al. For the UKCCCR Anal Cancer Trial Working Party. "Mind the Gap"-the impact of variations in the duration of the treatment gap and overall treatment time in the first UK Anal Cancer Trial (ACT I). Int J Radiat Oncol Biol Phys. 2011;81:1488-1494.
78. Janssen S, Meier zu Eissen J, Kolbert G, Bremer M, Karstens JH, Meyer A. Anal cancer treated with radio-chemotherapy: correlation between length of treatment interruption and outcome. Int J Colorectal Dis. 2009;24:1421-1428.
79. Oehler C, Provencher S, Donath D, Bahary JP, Lütolf UM, Ciernik IF. Chemo-radiation with or without mandatory split in anal carcinoma: experiences of two institutions and review of the literature. Radiat Oncol. 2010;5:36.
80. Zagar TM, Willett CG, Czito BG. Intensity-modulated radiation therapy for anal cancer: toxicity versus outcomes. Oncology (Williston Park). 2010;24:815-823, 828.
81. Engineer R, Mallik S, Mahantshetty U, Shrivastava S. Impact of radiation dose on locoregional control and survival on squamous cell carcinoma of anal canal. Radiother Oncol. 2010;95:283-287.
82. Roohipour R, Patil S, Goodman KA, et al. Squamous-cell carcinoma of the anal canal: predictors of treatment outcome. Dis Colon Rectum. 2008;51:147-153.
83. Das P, Bhatia S, Eng C, Ajani JA, et al. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys. 2007;68:794-800. (Pubitemid 46818735)
84. Ferenschild FT, Vermaas M, Hofer SO, Verhoef C, Eggermon AM, de Wilt JH. Salvage abdominoperineal resection and perineal wound healing in local recurrent or persistent anal cancer. World J Surg. 2005;29:1452-1457. (Pubitemid 41712681)
85. Papaconstantinou HT, Bullard KM, Rothenberger DA, Madoff RD. Salvage abdominoperineal resection after failed Nigro protocol: modest success, major morbidity. Colorectal Dis. 2006;8:124-129 (Pubitemid 43372460)
86. Stewart D, Yan Y, Kodner IJ, et al. Salvage surgery after failed chemoradiation for anal canal cancer: should the paradigm be changed for high-risk tumors? J Gastrointest Surg. 2007;11:1744-1751.
87. Schiller DE, Cummings BJ, Rai S, et al. Outcomes of salvage surgery for squamous cell carcinoma of the anal canal. Ann Surg Oncol. 2007;14:2780-2789. (Pubitemid 47460652)
88. Mullen JT, Rodriguez-Bigas MA, Chang GJ, et al. Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal. Ann Surg Oncol. 2007;14:478-483. (Pubitemid 46178331)
89. Goéré D, Bonnet S, Pocard M, Deutsch E, Lasser P, Elias D. Oncologic and functional results after abdominoperineal resection plus pseudocontinent perineal colostomy for epidermoid carcinoma of the anus. Dis Colon Rectum. 2009;52:958-963.
90. Lefevre JH, Parc Y, Kernéis S, et al. Abdomino-perineal resection for anal cancer: impact of a vertical rectus abdominis myocutaneous flap on survival, recurrence, morbidity, and wound healing. Ann Surg. 2009;250:707-711.
91. Vorob'ev GI, Shelygin IuA, Nechushkin MI, Rybakov EG. Results of surgical treatment of residual and recurrent anal tumors [in Russian] Khirurgiia (Mosk). 2008;(8):4-9.
92. Mariani P, Ghanneme A, De la Rochefordière A, Girodet J, Falcou MC, Salmon RJ. Abdominoperineal resection for anal cancer. Dis Colon Rectum. 2008;51:1495-1501.
93. Alcindor T. Activity of paclitaxel in metastatic squamous anal carcinoma. Int J Colorectal Dis. 2008;23:717.
94. Grifaichi F, Padovani A, Romeo F, Trinca C, Moscetti L, Cortesi E. Response of metastatic epidermoid anal cancer to single agent irinotecan: a case report. Tumori. 2001; 87:58-59. (Pubitemid 32273854)
95. Phan LK, Hoff PM. Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case. Dis Colon Rectum. 2007;50:395-398. (Pubitemid 46393970)
96. Faivre C, Rougier P, Ducreux M, et al. 5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer [in French]. Bull Cancer. 1999;86:861-865.
97. Eng C, Pathak P. Treatment options in metastatic squamous cell carcinoma of the anal canal. Curr Treat Options Oncol. 2008;9:400-407.
98. Lukan N, Ströbel P, Willer A, et al. Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. Oncology. 2009;77:293-299.
99. Nivatvongs S. Perianal and anal canal neoplasms. In: Gordon P, Nivatvongs S, eds. Principles and Practice of Surgery of the Colon, Rectum, and Anus. 2nd ed. St. Louis, MO: Quality Medical Publishing, Inc.; 1999:447-471.
100. Sischy B. The use of radiation therapy combined with chemotherapy in the management of squamous cell carcinoma of the anus and marginally respectable adenocarcinoma of the rectum. Int J Rad Oncol Biol Phys. 1985;11:1587-1593. (Pubitemid 15233620)
101. Golden GT, Horseley JS. Surgical management of epidermoid carcinoma of the anus. Am J Surg. 1976; 131:275-280.
102. Wright JL, Patil SM, Temple LK, Minsky BD, Saltz LB, Goodman KA. Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning. Int J Radiat Oncol Biol Phys. 2010;78:1064-1072.
103. Quan SH. Anal and perianal tumors. Surg Clin North Am. 1978;58:549-603.
104. Akbari RP, Paty PB, Guillem JG, et al. Oncologic outcomes of salvage surgery for epidermoid carcinoma of the anus initially managed with combined modality therapy. Dis Colon Rectum. 2004;47:1136-1144. (Pubitemid 38857060)
105. Melbye M, Cote T, Kessler L, et al. High incidence of anal cancer among AIDS patients. The AIDS/Cancer Working Group. Lancet. 1994;343:636-639. (Pubitemid 24087808)
106. Crum-Cianflone NF, Hullsiek KH, Marconi VC, et al. Infectious Disease Clinical Research Program HIV Working Group. Anal cancers among HIV-infected persons: HAART is not slowing rising incidence. AIDS. 2010;24:535-543.
107. Piketty C, Selinger-Leneman H, Grabar S, et al. Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS. 2008;22:1203-1211.
108. Hammad N, Heilbrun LK, Gupta S, et al. Squamous cell cancer of the anal canal in HIV-infected patients receiving highly active antiretroviral therapy: a single institution experience. Am J Clin Oncol. 2011;34:135-139.
109. Seo Y, Kinsella MT, Reynolds HL, Chipman G, Remick SC, Kinsella TJ. Outcomes of chemoradiotherapy with 5-fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients. Int J Radiat Oncol Biol Phys 2009;75:143-149.
110. Myerson RJ, Outlaw ED, Chang A, et al. Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience. Int J Radiat Oncol Biol Phys. 2009;75:428-435.
111. Hoffman R, Welton M, Klencke B, Weinberg V, Krieg R. The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. Int J Rad Oncol Biol Phys. 1999;44:127-131. (Pubitemid 29186199)
112. Cleator S, Fife K, Nelson M, Gazzard B, Phillips R, Bower M. Treatment of HIV-associated invasive anal cancer with combined chemoradiation. Eur J Cancer. 2000;36:754-758. (Pubitemid 30179747)
113. Place RJ, Gregorcyk SG, Huber PJ, Simmang CL. Outcome analysis of HIV-positive patients with anal squamous cell carcinoma. Dis Colon Rectum. 2001;44:506-512. (Pubitemid 32336424)
114. Wexler A, Berson AM, Goldstone SE, et al. Invasive anal squamous-cell carcinoma in the HIV-positive patient: outcome in the era of highly active antiretroviral therapy. Dis Colon Rectum. 2008;51:73-81.
115. Oehler-Jänne C, Huguet F, Provencher S, et al. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J Clin Oncol. 2008;26:2550-2557.
116. Papillon J, Mayer M, Montbarbon JF, Gerard JP, Chassard JL, Bailly C. A new approach to the management of epidermoid carcinoma of the anal canal. Cancer. 1983;51:1830-1837. (Pubitemid 13093951)
117. Longo WE, Vernava AM, Wade TP, et al. Recurrent squamous cell carcinoma of the anal canal: predictors of initial treatment failure and results of salvage therapy. Ann Surg. 1994;220:40-49. (Pubitemid 24205845)
118. Glynne-Jones R, Northover JM, Cervantes A. ESMO Guidelines Working Group. Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(suppl 5):v87-v92.
119. Haboubi NY, Edilbe MW, Hill J. Justification for staging of epidermoid anal carcinoma after salvage surgery: a pathological guideline. Colorectal Dis. 2007;9:238-244. (Pubitemid 46477027)
120. Martellucci J, Naldini G, Colosimo C, Cionini L, Rossi M. Accuracy of endoanal ultrasound in the follow-up assessment for squamous cell carcinoma of the anal canal treated with radiochemotherapy. Surg Endosc. 2009;23:1054-1057.
121. Tarantino D, Bernstein MA. Endoanal ultrasound in the staging and management of squamous-cell carcinoma of the anal canal: potential implications of a new ultrasound staging system. Dis Colon Rectum. 2002; 45: 16-22. (Pubitemid 34072747)
122. Christensen AF, Nielsen MB, Svendsen LB, Engelholm SA. Three-dimensional anal endosonography may improve detection of recurrent anal cancer. Dis Colon Rectum. 2006;49: 1527-1532. (Pubitemid 44796121)
123. Goh V, Gollub FK, Liaw J, et al. Magnetic resonance imaging assessment of squamous cell carcinoma of the anal canal before and after chemoradiation: can MRIpredict for eventual clinical outcome? Int J Radiat Oncol Biol Phys. 2010;78:715-721.
124. Koh DM, Dzik-Jurasz A, O'Neill B, Tait D, Husband JE, Brown G. Pelvic phased-array MR imaging of anal carcinoma before and after chemoradiation. Br J Radiol. 2008;81:91-98. (Pubitemid 351294205)
125. Roach SC, Hulse PA, Moulding FJ, Wilson R, Carrington BM. Magnetic resonance imaging of anal cancer. Clin Radiol. 2005; 60:1111-1119. (Pubitemid 41372366)
126. Schwarz JK, Siegel BA, Dehdashti F, Myerson RJ, Fleshman JW, Grigsby PW. Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer. Int J Radiat Oncol Biol Phys. 2008;71:180-186. (Pubitemid 351492591)
127. Vercellino L, Montravers F, de Parades V, et al. Impact of FDG PET/CT in the staging and the follow-up of anal carcinoma. Int J Colorectal Dis. 2011;26:201-210.
128. Nguyen BT, Joon DL, Khoo V, et al. Assessing the impact of FDG-PET in the management of anal cancer. Radiother Oncol. 2008;87:376-382.
129. Roldán GB, Chan AK, Buckner M, Magliocco AM, Doll CM. The prognostic value of hemoglobin in patients with anal cancer treated with chemoradiotherapy. Dis Colon Rectum. 2010;53:1127-1134.
130. Lampejo T, Kavanagh D, Clark J, et al. Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review. Br J Cancer. 2010;103:1858-1869.
131. Beahrs OH, Wilson SM. Carcinoma of the anus. Ann Surg. 1976;184:422-428.
132. Moore HG, Guillem JG. Anal neoplasms. Surg Clin North Am. 2002;82:1233-1251. (Pubitemid 36015522)
133. Greenall MJ, Quan SH, Stearns MW, et al. Epidermoid cancer of the anal margin: pathologic features, treatment, and clinical results. Am J Surg. 1985;149:95-101. (Pubitemid 15156162)
134. Papillon J, Chassard JL. Respective roles of radiotherapy and surgery in the management of epidermoid carcinoma of the anal margin: series of 57 patients. Dis Colon Rectum. 1992;35:422-429.
135. Cleary RK, Schaldenbrand JD, Fowler JJ, Schuler JM, Lampman RM. Perianal Bowen's disease and anal intraepithelial neoplasia: review of the literature. Dis Colon Rectum. 1999;42:945-951. (Pubitemid 29328468)
136. Darragh TM, Winkler B. The ABCs of anal-rectal cytology. College of American Pathologists. Available at: http://www.cap.org/apps/cap.portal. Accessed November 28, 2010.
137. Palefsky, JM, Holly, EA, Ralston, ML, et al. Anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual and bisexual men. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17:320-326.
138. Palefsky JM, Shiboski S, Moss A. Risk factors for anal human papilloma virus infection and anal cytologic abnormalities in HIV-positive and HIV-negative homosexual men. J Acquir Immune Defic Syndr. 1994;7:599-606.
139. Moscicki, AB, Hills, NK, Shiboski, S, et al. Risk factors for abnormal anal cytology in young heterosexual women. Cancer Epidemiol Biomarkers Prev. 1999;8:173.
140. Holmes F, Borek D, Owen-Kummer M, et al. Anal cancer in women. Gastroenterology. 1988;95:107-111.
141. Caussy D, Goedert JJ, Palefsky J, et al. Interaction of human immunodeficiency and papilloma viruses: association with anal epithelial abnormality in homosexual men. Int J Cancer. 1990; 46:214-219. (Pubitemid 20252079)
142. Friedman HB, Saah AJ, Sherman ME, et al. Human papillomavirus, anal squamous intraepithelial lesions, and human immunodeficiency virus in a cohort of gay men. J Infect Dis. 1998; 178:45-52. (Pubitemid 28328075)
143. Ogunbiyi OA, Scholefield JH, Raftery AT, et al. Prevalence of anal human papillomavirus infection and intraepithelial neoplasia in renal allograft recipients. Br J Surg. 1994;81:365-367. (Pubitemid 24124806)
144. Daling JR, Sherman KJ, Hislop TG, et al. Cigarette smoking and the risk of anogenital cancer. Am J Epidemiol. 1992;135:180-189.
145. Palefsky JM, Rubin M. The epidemiology of anal human papillomavirus and related neoplasia. Obstet Gynecol Clin North Am. 2009;36:187-200.
146. Chin-Hong PV, Berry JM, Cheng SC, et al. Comparison of patient- and clinician-collected anal cytology samples to screen for human papillomavirus-associated anal intraepithelial neoplasia in men who have sex with men. Ann Intern Med. 2008;149:300-306.
147. Palefsky J, Holly EA, Hogeboom CJ, et al. Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol. 1998; 17:314-319.
148. Schiffman MH, Castle P. Epidemiologic studies of a necessary causal risk factor: human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst. 2003;95:E2.
149. Holly EA, Ralston ML, Darragh TM, Greenblatt RM, Jay N, Palefsky JM. Prevalence and risk factors for anal squamous intraepithelial lesions in women. J Natl Cancer Inst. 2001;93:843-849. (Pubitemid 32586612)
150. Chin-Hong PV, Vittinghoff E, Cranston RD, et al. Age related prevalence of anal cancer precursors in homosexual men: the EXPLORE study. J Natl Cancer Inst. 2005; 97:896-905. (Pubitemid 41417941)
151. Pineda CE, Welton ML. Controversies in the management of anal high-grade squamous intraepithelial lesions. Minerva Chir. 2008;63:389-399.
152. Watson AJ, Smith BB, Whitehead MR, et al. Malignant progression of anal intra-epithelial neoplasia. ANZ J Surg. 2006;76:715-717. (Pubitemid 44154742)
153. Scholefield JH, Castle MT, Watson NF. Malignant transformation of high-grade anal intraepithelial neoplasia. Br J Surg. 2005; 92:1133-1136. (Pubitemid 41284878)
154. Devaraj B, Cosman BC. Expectant management of anal squamous dysplasia in patients with HIV. Dis Colon Rectum. 2006;49:36-40. (Pubitemid 41830653)
155. Arain S, Walts AE, Thomas P, Bose S. The anal Pap smear: cytomorphology of squamous intraepithelial lesions. Cytojournal. 2005; 2:4.
156. Palefsky JM, Holly EA, Hogeboom CJ, Berry JM, Jay N, Darragh TM. Anal cytology as a screening tool for anal squamous intraepithelial lesions. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14:415-422.
157. Fox PA, Seet JE, Stebbing J, et al. The value of anal cytology and human papillomavirus typing in the detection of anal intraepithelial neoplasia: a review of cases from an anoscopy clinic. Sex Transm Infect. 2005;81:142-146. (Pubitemid 40523826)
158. Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Welton ML, Palefsky JM. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA. 1999;281:1822-1829. (Pubitemid 29231133)
159. Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Palefsky JM. Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men. Am J Med. 2000;108:634-641. (Pubitemid 30336603)
160. Chang GJ, Berry JM, Jay N, et al. Surgical treatment of high-grade anal squamous intraepithelial lesions: a prospective study. Dis Colon Rectum. 2002;45:453-458. (Pubitemid 34407722)
161. Pineda CE, Berry JM, Jay N, Palefsky JM, Welton ML. High resolution anoscopy in the planned staged treatment of anal squamous intraepithelial lesions in HIV-negative patients. J Gastrointest Surg. 2007;11:1410-1416.
162. Pineda CE, Berry JM, Jay N, Palefsky JM, Welton ML. High-resolution anoscopy targeted surgical destruction of anal high-grade squamous intraepithelial lesions: a ten-year experience. Dis Colon Rectum. 2008;51:829-837.
163. Valari O, Koliopoulos G, Karakitsos P, et al. Human papillomavirus DNA and mRNA positivity of the anal canal in women with lower genital tract HPV lesions: predictors and clinical implications. Gynecol Oncol. 2011;122:505-508.
164. Mahto M, Nathan M, O'Mahony C. More than a decade on: review of the use of imiquimod in lower anogenital intraepithelial neoplasia. Int J STD AIDS. 2010;21:8-16.
165. Wieland U, Brockmeyer NH, Weissenborn SJ, et al. Imiquimod treatment of anal intraepithelial neoplasia in HIV-positive men. Arch Dermatol. 2006;142:1438-1444. (Pubitemid 44790637)
166. Rosen T, Harting M, Gibson M. Treatment of Bowen's disease with topical 5% imiquimod cream: retrospective study. Dermatol Surg. 2007;33:427-432.
167. Wendling J, Saiag P, Berville-Levy S, Bourgault-Villada I, Clerici T, Moyal-Barracco M. Treatment of undifferentiated vulvar intraepithelial neoplasia with 5% imiquimod cream: a prospective study of 12 cases. Arch Dermatol 2004; 140:1220-1224. (Pubitemid 39362239)
168. Beutner KR, Spruance SL, Hougham AJ, Fox TL, Owens ML, Douglas JM Jr. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol. 1998;38:230-239. (Pubitemid 28100838)
169. Moore RA, Edwards JE, Hopwood J, Hicks D. Imiquimod for the treatment of genital warts: a quantitative systematic review. BMC Infect Dis. 2001;1:3.
170. Kreuter A, Potthoff A, Brockmeyer NH, et al. German Competence Network HIV/AIDS. Imiquimod leads to a decrease of human papillomavirus DNA and to a sustained clearance of anal intraepithelial neoplasia in HIV-infected men. J Invest Dermatol. 2008;128:2078-2083. (Pubitemid 352001209)
171. Schmidt KU, Wiskemann A, Mensing H. Etretinate and 5-fluorouracil in intra-anal Bowen's disease [in German] Hautarzt. 1986;37:278-280. (Pubitemid 16115828)
172. Bargman H, Hochman J. Topical treatment of Bowens disease with 5-fluorouracil. J Cutan Med Surg. 2003;7:101-105. (Pubitemid 36506157)
173. Cox NH, Eedy DJ, Morton CA. Guidelines for management of Bowens disease: 2006 update. Br J Dermatol. 2007;156:11-21. (Pubitemid 44924139)
174. Richel O, Wieland U, De Vries HJ, et al. Topical 5-fluorouracil treatment of anal intraepithelial neoplasia in human immunodeficiency virus-positive men. Br J Dermatol. 2010;163:1301-1307.
175. Graham BD, Jetmore AB, Foote JE, et al. Topical 5-fluorouracil in the management of extensive anal Bowen's disease: a preferred approach. Dis Colon Rectum. 2005;48:444-450. (Pubitemid 40767863)
176. Petrelli NJ, Cebollero JA, Rodriguez-Bigas M, Mang T. Photodynamic therapy in the management of neoplasms of the perianal skin. Arch Surg. 1992;127:1436-1438.
177. Allison RR, Sheng C, Cuenca R, Bagnato VS, Austerlitz C, Sibata CH. Photodynamic therapy for anal cancer. Photodiagnosis Photodyn Ther. 2010;7:115-119.
178. Kruijt B, van der Snoek EM, Sterenborg HJ, Amelink A, Robinson DJ. A dedicated applicator for light delivery and monitoring of PDT of intra-anal intraepithelial neoplasia. Photodiagnosis Photodyn Ther. 2010;7:3-9.
179. van der Snoek EM, Amelink A, van der Ende ME, et al. Photodynamic therapy with topical metatetrahydroxychlorin (Fosgel) is ineffective for the treatment of anal intraepithelial neoplasia, grade III . J Acquir Immune Defic Syndr. 2009;52:141-143.
180. Hamdan KA, Tait IS, Nadeau V, Padgett M, Carey F, Steele RJ. Treatment of grade III anal intraepithelial neoplasia with photodynamic therapy: report of a case. Dis Colon Rectum. 2003;46:1555-1559. (Pubitemid 37429740)
181. Scholefield JH. Treatment of grade III anal intraepithelial neoplasia with photodynamic therapy: report of a case. Dis Colon Rectum., 2003;46:1555-1559.
182. Strauss RJ, Fazio VW. Bowen's disease of the anal and perianal area: a report and analysis of twelve cases. Am J Surg. 1979;137:231-234. (Pubitemid 9092119)
183. Margenthaler JA, Dietz DW, Mutch MG, et al. Outcomes, risk of other malignancies, and need for formal mapping procedures in patients with perianal Bowen's disease. Dis Colon Rectum. 2004; 47:1655-1661.
184. Brown SR, Skinner P, Tidy J, Smith JH, Sharp F, Hosie KB. Outcome after surgical resection for high-grade anal intraepithelial neoplasia (Bowen's disease). Br J Surg. 1999; 8:1063-1066. (Pubitemid 29387074)
185. Marchesa P, Fazio VW, Oliart S, Goldblum JR, Lavery IC. Perianal Bowen's disease: a clinicopathologic study of 47 patients. Dis Colon Rectum. 1997;40:1286-1293. (Pubitemid 27498363)
186. Chung AP, Rosenfeld DB. Intraoperative high-resolution anoscopy: a minimally invasive approach in the treatment of patients with Bowen's disease and results in a private practice setting. Am Surg. 2007;73:1279-1283. (Pubitemid 351396507)
187. Goldstone SE, Hundert JS, Huyett JW. Infrared coagulator ablation of high-grade anal squamous intraepithelial lesions in HIV-negative males who have sex with males. Dis Colon Rectum. 2007; 50:565-575. (Pubitemid 46876492)
188. Goldstone SE, Kawalek AZ, Huyett JW. Infrared coagulator: a useful tool for treating anal squamous intraepithelial lesions. Dis Colon Rectum. 2005;48:1042-1054. (Pubitemid 40894628)
189. Chang GJ, Welton ML. Anal neoplasia. Semin Colon Rectal Surg. 2003;14:111-118. (Pubitemid 36944758)
190. Jay N, Berry JM, Hogeboom CJ, Holly EA, Darragh TM, Palefsky JM. Colposcopic appearance of anal squamous intraepithelial lesions: relationship to histopathology. Dis Colon Rectum. 1997;40:919-928. (Pubitemid 27355394)
191. Chin-Hong PV, Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis. 2002;35:1127-1134. (Pubitemid 35239474)
192. Kim JJ. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis. 2010;10:845-852.
193. Wilkin T, Lee JY, Lensing SY, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis. 2010;202:1246-1253.
194. Anderson JS, Hoy J, Hillman R, et al. A randomized, placebo-controlled, dose-escalation study to determine the safety, tolerability, and immunogenicity of an HPV-16 therapeutic vaccine in HIV-positive participants with oncogenic HPV infection of the anus. J Acquir Immune Defic Syndr. 2009;52:371-381.
195. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med. 2008;359:821-832.